EGFR and non-small cell lung carcinoma: In patients with disease progression despite EGFR TKI therapy (including second-line osimertinib), treatment may be switched to afatinib plus cetuximab [6]; and, finally, possibly switching to combination chemotherapy based on the NSCLC cell type (i.e., lung adenocarcinoma or squamous cell carcinoma).